Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P35625

UPID:
TIMP3_HUMAN

ALTERNATIVE NAMES:
Protein MIG-5; Tissue inhibitor of metalloproteinases 3

ALTERNATIVE UPACC:
P35625; B2RBY9; Q5THV4; Q9UC74; Q9UGS2

BACKGROUND:
Metalloproteinase inhibitor 3, with alternative names Protein MIG-5 and Tissue inhibitor of metalloproteinases 3, is integral to the body's response to tissue damage. It irreversibly inactivates several metalloproteinases by binding to their zinc cofactor, highlighting its pivotal role in tissue repair and remodeling processes.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in inhibiting metalloproteinases and its association with Sorsby fundus dystrophy, Metalloproteinase inhibitor 3 represents a promising target for therapeutic intervention. Exploring its mechanisms further could lead to breakthroughs in treating vision-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.